Start with colon versus rectal cancer, stage, surgery status, exact biomarker results and prior treatment. A study before surgery, after surgery or after metastatic treatment may have very different entry requirements.
Answer a few questions to find clinical trials matched to your specific Colorectal Cancer situation.
A thorough search takes ~15 minutes — we'll email your results. No sign-up.
Colon versus rectal: surgery, radiation, staging and organ-preservation protocols differ.
Before or after surgery: neoadjuvant studies may require untreated disease; adjuvant trials may set a postoperative enrollment window and specific pathological-risk criteria.
Metastatic disease: first-line and refractory studies differ in required chemotherapy, biologics, documented progression and prior HER2 or immune treatment.
Limited or liver-only spread: resectability, number/location of metastases and suitability for local treatment are protocol-specific.
Current Clinical Trial Landscape
Registry snapshot, November 15, 2026: the worldwide ClinicalTrials.gov search for Colorectal Cancer, interventional studies and Recruiting status returned 1,182 records. This is a broad result, not 1,182 personally suitable trials. Open the filtered registry search.
Research areas include biomarker-selected treatment, immunotherapy combinations, ADCs, organ preservation, postoperative treatment and liver-directed approaches. Categories overlap; fresh class-specific totals are not claimed.
Biomarkers and Treatment History to Bring
MSI/MMR: record MSI-H/dMMR or MSS/pMMR and the test result. These select different immunotherapy protocols; MSS studies may explicitly exclude dMMR.
KRAS/NRAS and BRAF: record the exact variant or tested wild-type result. KRAS G12C is different from G12D/G12V; BRAF V600E differs from other BRAF findings. Some EGFR-directed trials also require left-sided disease.
HER2: bring IHC, ISH/FISH and molecular reports, plus all prior anti-HER2 drugs. Amplification, mutation and IHC 3+ expression are different selection criteria, not interchangeable labels.
ctDNA: note assay, sample timing and any prior positive/negative results. A negative result does not prove no residual cancer and is not, by itself, permission to skip chemotherapy.
Previous treatment: list fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF/EGFR drugs, immunotherapy and HER2 agents with dates and reasons for stopping.
Approved Treatment and Trial Enrollment Are Different
Selected U.S. examples illustrate why setting and biomarkers matter:
These are selected examples, not a complete treatment recommendation. Discuss current local labels and standard-care alternatives with your oncology team.
What ctDNA-Guided Research Does—and Does Not—Establish
Postoperative ctDNA can help study recurrence risk, but risk prediction and proof that changing treatment improves outcomes are different questions. Test timing, assay sensitivity, stage and pathological risk matter. Do not infer that every ctDNA-positive patient benefits from escalation or every negative patient can safely omit treatment. The studies below test defined strategies; follow the study protocol and oncology advice.
ASCO's 2026 ctDNA guideline describes evidence limitations and does not make a general recommendation for recurrence monitoring. This page does not recommend stopping, escalating or omitting treatment on a ctDNA result alone.
Have your stage, biomarker reports and treatment history ready?
All 49 cited records were checked November 15, 2026: 39 recruiting, seven not yet recruiting, two active but not recruiting and one unknown. Non-enrolling and unknown-status examples are separated at the end. Each example has its phase and recruitment label; site and cohort availability still need confirmation.
dMMR/MSI-H rectal and colon studies around surgery
NCT04165772 — Induction dostarlimab for locally advanced dMMR solid tumors, including the rectal organ-preservation program; nonoperative management requires a clinical complete response and surveillance (Phase 2; recruiting).
NCT06762405 — PRODIGE 90: neoadjuvant dostarlimab with short-course radiotherapy within a watch-and-wait strategy for dMMR/MSI-H locally advanced rectal adenocarcinoma (Phase 3; recruiting).
NCT05239546 — Neoadjuvant dostarlimab for stage II–III dMMR colon cancer; colon and rectal protocols are not interchangeable (Phase 2; recruiting).
NCT07412613 — Cadonilimab before/after surgery versus adjuvant chemotherapy for resectable stage IIB–III dMMR/MSI-H colon cancer (Phase 3; recruiting).
NCT05236972 — PACE: PD-1 antibody for dMMR/MSI-H stage III colorectal cancer (Phase 3; recruiting).
NCT06520683 — Adjuvant PD-1 blockade for high-risk stage II dMMR/MSI-H colorectal cancer (Phase 3; recruiting).
Rectal organ preservation and other local/neoadjuvant studies
NCT03051464 — No Surgery Trial: two radiotherapy-boost approaches after chemoradiation for selected T2–T3 rectal cancer; not a dMMR-specific immunotherapy trial (Phase 2/3; recruiting).
NCT06229041 — TNTi: total neoadjuvant treatment with or without immunotherapy followed by surgery for high-risk locally advanced rectal cancer; MSI-H/dMMR is excluded (Phase 3; recruiting).
NCT07070622 — OPLAR: planned organ preservation for low rectal cancer after neoadjuvant chemotherapy; response and local-treatment criteria apply (Phase 3; recruiting).
NCT06205485 — Chemotherapy followed by local excision/observation versus chemoradiotherapy for selected pMMR cN0/M0 rectal tumors; not a general high-risk locally advanced population (Phase 3; recruiting).
NCT05194878 — Neoadjuvant FOLFOXIRI versus immediate surgery for stage II–III colon cancer (Phase 3; recruiting).
NCT06791512 — mFOLFOX6/bevacizumab/PD-1 antibody versus mFOLFOX6 for locally advanced pMMR/MSS colorectal cancer; this is a neoadjuvant/local setting (Phase 3; recruiting).
NCT06280495 — Neoadjuvant serplulimab/bevacizumab/FOLFOX versus FOLFOX in RAS/BRAF-wild-type pMMR/MSS disease (Phase 2/3; recruiting).
NCT07228832 — HARMONi-GI3: ivonescimab plus FOLFOX versus bevacizumab plus FOLFOX first-line for metastatic disease; MSI-H/dMMR is excluded (Phase 3; recruiting).
NCT07221357 — Pumitamig plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated unresectable/metastatic disease, without known dMMR/MSI-H (Phase 2/3; recruiting).
NCT07284849 — Standard chemotherapy/bevacizumab with or without INCA33890 first-line for metastatic MSS colorectal cancer (Phase 3; recruiting).
NCT06566755 — Cadonilimab plus chemotherapy/bevacizumab first-line for RAS-mutant or right-sided metastatic MSS disease (Phase 3; recruiting).
MSS/pMMR previously treated advanced disease
NCT06497985 — Tucidinostat/sintilimab/bevacizumab versus fruquintinib in MSS/pMMR disease; prior-treatment and prior-immunotherapy restrictions apply (Phase 3; recruiting).
NCT07722494 — IBI363 plus bevacizumab for pMMR/MSS advanced disease refractory or intolerant to standard therapy; not a first-line regimen (Phase 3; recruiting).
KRAS G12C first-line studies
NCT06252649 — Sotorasib/panitumumab/FOLFIRI versus FOLFIRI with or without bevacizumab in treatment-naive KRAS G12C metastatic disease (Phase 3; recruiting).
NCT06997497 — KANDLELIT-012: calderasib/cetuximab/mFOLFOX6; the randomized part is first-line KRAS G12C unresectable/metastatic disease, with protocol-defined prior-treatment exceptions (Phase 3; recruiting).
RAS/BRAF wild-type EGFR-directed studies
NCT06662786 — Amivantamab plus mFOLFOX6 or FOLFIRI versus cetuximab plus the same chemotherapy first-line for left-sided KRAS/NRAS/BRAF-wild-type unresectable/metastatic disease (Phase 3; recruiting).
NCT06750094 — Amivantamab/FOLFIRI versus cetuximab or bevacizumab/FOLFIRI after one fluoropyrimidine/oxaliplatin-based metastatic line in KRAS/NRAS/BRAF-wild-type disease (Phase 3; recruiting).
NCT07702032 — LiGeR-CRC1: petosemtamab plus chemotherapy versus cetuximab plus chemotherapy for RAS/BRAF-wild-type left-sided unresectable/metastatic disease (Phase 3; recruiting).
NCT07775287 — LiGeR-CRC2: petosemtamab plus chemotherapy versus cetuximab or bevacizumab plus chemotherapy for RAS/BRAF-wild-type recurrent/unresectable/metastatic disease in a later-line setting (Phase 3; recruiting).
BRAF V600 basket study
NCT05768178 — DETERMINE Arm 05: vemurafenib plus cobimetinib for actionable BRAF V600-mutant cancers; basket and master-protocol criteria apply (Phase 2/3; recruiting).
HER2-positive metastatic disease: first-line research
NCT05253651 — MOUNTAINEER-03: tucatinib/trastuzumab/mFOLFOX6 versus standard treatment first-line for HER2-positive metastatic colorectal cancer (Phase 3; recruiting).
HER2-selected previously treated disease and exploratory cohorts
NCT06695845 — Zanidatamab basket for centrally confirmed HER2 IHC 3+ tumors after prior treatment; the CRC-containing cohort does not permit prior HER2-targeted therapy (Phase 2; recruiting).
NCT07653685 — TQB2930 plus chemotherapy with or without bevacizumab for HER2-abnormally-expressed unresectable/metastatic colorectal cancer; assay and cohort requirements apply, and MSI-H/dMMR is excluded (Phase 1/2; recruiting).
NCT05786716 — DETERMINE Arm 04: trastuzumab plus pertuzumab for selected HER2-amplified or activating-mutant cancers; basket/master-protocol and local treatment-option criteria apply (Phase 2/3; recruiting).
Previously treated metastatic disease: ADC research
NCT07549412 — PROCEADE-CRC-03: precemtabart tocentecan with or without bevacizumab versus trifluridine/tipiracil plus bevacizumab in previously treated metastatic colorectal cancer (Phase 3; recruiting).
NCT07525206 — Telisotuzumab adizutecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer; drug target does not by itself establish a MET-selection requirement (Phase 3; recruiting).
Postoperative ctDNA-guided research
NCT05174169 — Adjuvant colon chemotherapy based on residual-disease evaluation; escalation/de-escalation follows the study protocol (Phase 2/3; recruiting).
NCT05954078 — ctDNA methylation-guided postoperative chemotherapy for high-risk stage II/III colorectal cancer (Phase 3; recruiting).
NCT05534087 — ctDNA-directed adjuvant chemotherapy platform in colon cancer (Phase 3; recruiting).
Limited metastatic disease, liver-directed treatment and dosing research
NCT06857773 — Hepatic arterial infusion pump plus systemic therapy for initially unresectable colorectal liver metastases (Phase 3; recruiting).
NCT06185556 — COLDFIRE-III: irreversible electroporation and stereotactic radiation strategies for perivascular/peribiliary colorectal liver metastases (Phase 2/3; recruiting).
NCT05673148 — ERASur: total ablative therapy added to systemic treatment for limited metastatic colorectal cancer (Phase 2; recruiting).
NCT06642844 — Bevacizumab-based chemotherapy with pharmacokinetic-adapted dosing first-line for unresectable metastatic disease (Phase 3; recruiting).
Not yet recruiting
NCT07384377 — JSKN003 versus physician-selected treatment after oxaliplatin, fluoropyrimidine and irinotecan failure; HER2 IHC 3+ or IHC 2+/FISH-positive, BRAF V600E wild-type; this is not first-line (Phase 3; not yet recruiting).
NCT07483684 — TQB2102 versus investigator choice after prior oxaliplatin/irinotecan/fluoropyrimidine treatment in centrally confirmed HER2 IHC 3+ advanced disease; this is not first-line (Phase 3; not yet recruiting).
NCT05985707 — KN026 plus chemotherapy with or without KN046 for HER2-positive colorectal or biliary cancer (Phase 2; not yet recruiting).
NCT07059338 — Dual EGFR/HER2 blockade plus irinotecan for HER2-positive metastatic colorectal cancer (Phase 2; not yet recruiting).
NCT07243938 — UNION-HER2-BASKET: zanidatamab plus tislelizumab for HER2-positive gastrointestinal tumors (Phase 2; not yet recruiting).
NCT07631871 — Zanidatamab after at least one standard line for HER2-positive advanced tumors (Phase 2; not yet recruiting).
NCT07631884 — Trastuzumab rezetecan for HER2-expressing advanced solid tumors (Phase 2; not yet recruiting).
Active, not recruiting
NCT05723562 — AZUR-1: dostarlimab for untreated dMMR/MSI-H locally advanced rectal cancer; this is Phase 2, not Phase 3 (Phase 2; active not recruiting).
NCT03803553 — Identification/treatment of micrometastatic disease in stage III colon cancer (Phase 3; active not recruiting).
Recruitment unknown: confirm before considering enrollment
NCT06017583 — Neoadjuvant chemotherapy/PD-1 blockade/SIB-IMRT for locally advanced rectal cancer; registry recruitment status is unknown (Phase 3; unknown).
Not yet recruiting means new enrollment has not started; active, not recruiting means treatment/follow-up may continue without new enrollment. Unknown status requires current confirmation and must not be treated as open.
Frequently Asked Questions
How do I find colorectal cancer trials for my biomarkers?
Start with colon versus rectal cancer, stage and resectability, MSI/MMR, exact RAS/BRAF and HER2 findings, prior treatment and location. ClinTrialFinder suggests studies for discussion; the study team confirms eligibility and availability.
How many colorectal cancer trials are recruiting?
The November 15, 2026 worldwide ClinicalTrials.gov query for Colorectal Cancer, interventional studies and Recruiting status returned 1,182 records. This broad search is not a personalized count. Of the 49 selected records here, 39 were recruiting; nine were not open to new enrollment and one had unknown status.
Do MSI-H/dMMR and MSS/pMMR use the same trials?
Often not. Some immunotherapy protocols require MSI-H/dMMR, while others select MSS/pMMR and exclude dMMR. Stage and colon versus rectal location also matter. TNTi (NCT06229041), for example, excludes MSI-H/dMMR despite studying immunotherapy in rectal cancer.
Can a negative ctDNA test mean I can skip chemotherapy?
Not on its own. A negative ctDNA result can miss residual disease, and treatment decisions also depend on stage, pathology, prior treatment, test timing and the evidence for a specific strategy. The postoperative trials here test defined escalation or de-escalation approaches; discuss treatment with your oncology team.
Which HER2-positive metastatic colorectal trials are first-line versus refractory?
MOUNTAINEER-03 (NCT05253651) studies tucatinib/trastuzumab/mFOLFOX6 first-line. JSKN003 (NCT07384377) and TQB2102 (NCT07483684) require prior chemotherapy failure and were not yet recruiting on November 15; they are not first-line options. IHC/ISH thresholds, RAS/BRAF results and prior HER2 exposure differ by protocol.
Can organ-preservation trials guarantee that rectal surgery is avoided?
No. Studies use different biomarker, stage and response requirements. Clinical complete response and close surveillance are important in nonoperative approaches, and further surgery or radiation may still be needed. Colon protocols should not be substituted for rectal protocols.
Find Colorectal Cancer Trials Matched to Your Situation
Enter your MSI/MMR status, RAS/BRAF mutations, and treatment history to get AI-matched results in minutes.
This page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or healthcare team. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here.